Comment by Nicola Tommasi (Galimberti’s Lab)
Chemotherapeutic agents (Anthracyclines) and the inhibitor of the human epidermal growth factor receptor 2 (Trastuzumab) are often prescribed for the treatment of breast cancer; however, their cardiotoxicity limit the clinical use of these powerful agents. About this, our PhD student Martina Arici (Rocchetti’s Lab ) contributed to an article recently published on Frontiers in Physiology entitled “Structural and electrophysiological changes in a model of cardiotoxicity induced by anthracycline combined with Trastuzumab”.
Check out the full open access article at this link: https://doi.org/10.3389/fphys.2021.658790
Congratulation for this achievement!
#BtBsPhD #PhDStudents #TeCSBi #TeCSBiSpotlight #RocchettiLab_BtBs #GalimbertiLab_BtBs